A Comparative Study of Efficacy and Adverse Effects Between Alfuzosin and Tamsulosin in the Treatment of Benign Prostatic Hyperplasia

Rahman MM,1 Alam SMM,2 Amin MN3

ABSTRACT

Background & Objective: Before the advent of medical therapy for BPH causing lower urinary tract obstructive symptoms (LUTS), the treatment was primarily a surgical one with higher morbidities and inconsistent outcomes. With the advent of alpha-antagonists, the face of BPH treatment took a new look. Currently most of the medical managements of BPH includes α-1 adrenoceptor antagonists. Of them tamsulosin and alfuzosin are commonly used with different efficacies and side-effects being claimed. The present study was done to compare the safety and efficacy of tamsulosin and alfuzosin in the treatment LUTS suggestive of BPH.

Patients & Methods: The present prospective randomised clinical trial was conducted at the Department of Urology, Chittagong Medical College Hospital to compare the outcomes of tamsulosin and alfuzosin in the treatment of LUTS suggestive of benign hyperplasia of prostate (BPH). A total of 80 subjects selected for the study were randomly assigned to alfuzosin (n = 40) and tamsulosin (n = 40) groups. Alfuzosin 10 mg and tamsulosin 0.4 mg as once-daily doses were given to the patients of respective groups for consecutive 12 weeks with no initial dose titration. Of the 80 patients, 67 patients - 36 in the alfuzosin and 31 in the tamsulosin groups finally completed the treatment as per protocol. The outcome was evaluated at the end of month 1 and 2 in terms of IPSS, Qmax, PVR and complications encountered.

Result: The mean ages of alfuzosin and tamsulosin groups were 66.5 and 62.3 years respectively. The mean IPSS, Qmax and PVR at baseline were homogeneously distributed between groups (p = 0.217, p = 0.394, p = 0.174). At the endpoint, IPSS and PVR were significantly less in tamsulosin group than those in alfuzosin group (p = 0.015 and p = 0.038 respectively). The Qmax responded well in both the groups with no significant inter-group difference (p = 0.453). The alfuzosin group had a significantly higher postural hypotension, dizziness, asthma and GI tract upset compared to the tamsulosin group. However, tachycardia, headache and rhinitis were more common in the tamsulosin group than those in the alfuzosin group. At the endpoint alfuzosin group experienced a significant reduction in blood pressure compared to their baseline figures (p < 0.001). In the tamsulosin group the diastolic blood pressure decreased slightly in the 1st month of treatment, but they again stabilized during 2nd month of treatment, while systolic blood pressure did not experience any change. Both treatment groups exhibited an improvement of Qmax 3 ml/s from baseline. However, improvement of total symptom score in terms of IPSS 25% from baseline was significantly higher in the alfuzosin group (88.9%) than that in the tamsulosin group (48.9%; p < 0.001).

Conclusion: Tamsulosin is a better than alfuzosin for patients with LUTS suggestive of BPH who are normotensive or hypertensive but well-controlled with conventional antihypertensives.

Key words: Tamsulosin, alfuzosin, lower urinary tract symptoms & benign prostatic hyperplasia.

Introduction

Benign prostatic hyperplasia (BPH) is the non malignant enlargement of the prostate gland. Prior to 1980s, the primary treatment of symptomatic BPH was surgical, the morbidities of which were immense and outcomes were always inconsistent. With our increased understanding of the neurologic and hormonal function of the prostate, medical management has become the primary therapy for lower urinary tract symptoms (LUTS).1

Of the medical managements, androgen-deprivation therapy (with GnRH agonists, antiandrogens, or 5a-reductase inhibitors) is effective because it reduces the static component of benign prostatic hyperplasia. Among these agents, the 5 α-reductase inhibitors are the most promising because of their low toxicity. Because the prostate gland is an androgen-sensitive organ, androgen deprivation decreases the size of the prostate and the resistance to outflow through the prostatic urethra with consequent improvement in the ability of patients to urinate.2,3

Currently alpha-antagonists are the most widely prescribed medical therapy for BPH, encompassing more than 90% of the new prescriptions (Bullock, 2006)1. Of them tamsulosin and alfuzosin being commonly used with different efficacies and side-effects reported by different investigators. Buzelin4 reported a comparable efficacy between tamsulosin (0.4 mg as once daily dose) and alfuzosin (as thrice daily dose) in the treatment of symptomatic benign hyperplasia of prostate and both treatment were well-tolerated. The main difference between the

Authors’ Information
1 Dr. Md. Mizanur Rahman, MBBS, MS (Uro), Department of Urology, Chittagong Medical College.
2 Dr. S. M. Mahbub Alam, MBBS, FCPS, MS (Uro), Prof. & Head, Department of Urology, Dhaka Medical College.
3 Dr. Md. Nurul Amin, Research Specialist, Ibrahimb Cardiac Hospital & Research Institute, Dhaka, Bangladesh
Correspondence: Dr. Md. Mizanur Rahman, Mobile: 01713-609432.
drugs was that tamsulosin had significantly less effect on blood pressure than alfuzosin in patients over 65 years old. On the other hand, alfuzosin being a clinically uroselective alpha-blocker, demonstrated its efficacy and safety (in two large double-blind trials) over placebo in terms of maximum urinary flow rates, BPH symptoms, and quality of life (QOL), with changes in blood pressure or ejaculatory disturbances.\(^1\)

However, the efficacy and safety of the two drugs documented were all the results of placebo-controlled trial\(^5,6\) the comparison of the two drugs in a head-to-head trial is very rare. Recently these drugs are being marketed in our country, though no study has yet been conducted in the context of our population. Urologists are also gradually becoming inclined towards medical treatment of BPH. So prescribing these drugs without any formal study report regarding its efficacy, safety and long-term effect is like throwing stones in the dark. The present study was, therefore, conducted to see which of the two drugs - tamsulosin and alfuzosin - is better (in terms of efficacy and safety) in the treatment of lower urinary tract symptoms (LUTS) caused by benign hyperplasia of prostate (BPH).

**Patients & Methods**

The present prospective randomised clinical trial was conducted at the Department of Urology, Chittagong Medical College Hospital to compare the efficacy and safety of tamsulosin and alfuzosin in the treatment of LUTS suggestive of benign hyperplasia of prostate (BPH). A total of 80 subjects selected for study were randomly assigned to Alfuzosin (n = 40) and Tamsulosin (n = 40) groups. Men aged > 50 years with a clinical diagnosis of symptomatic BPH or at least 6-months history of lower urinary tract symptoms, an International Prostate Symptom Score (IPSS) of >13 and a peak flow rate (Q\(_{\text{max}}\)) of 5 - 12 ml/sec for voided volume of >120 ml, and a post voidal residual urine volume (PVR) of >150 ml were included in the study. Patients with concomitant urological diseases, diagnosed or suspected carcinoma of the prostate, hepatic or renal failure, previous bladder neck, prostate or pelvic region surgery, patients with Parkinson's disease, insulin-dependent diabetes, diagnosed or suspected multiple sclerosis, unstable angina or severe heart failure, cerebrovascular disease or CNS disorders were excluded from the study. A history of orthostatic hypotension or syncope on the day '0' (prior to start of treatment), life-threatening previous allergic reactions to \(\alpha\)-1-adrenoceptor antagonists, patients previously showing no improvement with treatment with an \(\alpha\)-blocker, or patients concomitantly taking drugs like other \(\alpha\)-adrenoceptor antagonists, \(\alpha\)-adrenoceptor agonists or anticholinergic drugs or calcium antagonists were also excluded.

Alfuzosin 10 mg and tamsulosin 0.4 mg as once-daily doses were given to the patients of respective groups for consecutive 12 weeks with no initial dose titration. Of the 80 patients, 67 patients - 36 in the alfuzosin and 31 in the tamsulosin groups finally completed the treatment as per protocol and hence were considered as evaluable. The outcome was evaluated at the end of month 1 and 2 in terms of IPSS, Q\(_{\text{max}}\), PVR and complications encountered. Data were analysed using Chi-square (\(\chi^2\)) or Fisher's Exact Test, Student's t-Test, paired sample t-Test and repeated measure ANOV.

**Results**

All the clinical symptoms, except nocturia, painful urination and obstructive uropathy at baseline were almost identically distributed between groups (table I). Nocturia and obstructive uropathy were significantly higher in the tamsulosin group (83.9% and 16.1% respectively) than those in the alfuzosin group (16.7% and 0% respectively) (p < 0.001 and p = 0.018), while painful urination was almost invariably present in the alfuzosin group (94.4%) than that in the tamsulosin group (71%) (p = 0.010). The mean IPSS, Q\(_{\text{max}}\) (ml/sec), PVR all were homogeneously distributed between groups (p = 0.217, p = 0.394, p = 0.174). However, systolic and diastolic blood pressures at standing and on lying positions were significantly higher in the alfuzosin group than those in the tamsulosin group (p < 0.001) (table -I).

All the outcome variables in alfuzosin group like IPSS, Q\(_{\text{max}}\) and PVR improved significantly at month 1 from their baseline status. The mean IPSS decreased from 17.3 at baseline to 13.6 at month 1 (p < 0.001). The mean Q\(_{\text{max}}\) increased from 11 ml/sec at baseline to 13.1 ml/sec at month 1 (p < 0.001). The PVR reduced from 87.2 ml at baseline to 74.6 ml after month 1. The systolic and diastolic blood pressures also decreased to normal range (p < 0.001). Likewise in tamsulosin group, all the outcome variables improved significantly at month 1 from their baseline status. The mean IPSS decreased from 16.9 at baseline to 13.1 at month 1 (p < 0.001). The mean Q\(_{\text{max}}\) increased from 11.2 ml/sec at baseline to 13.3 ml/sec at month 1 (p < 0.001). The PVR reduced from 115.8 ml at baseline to 74.8 ml after month 1 (p < 0.001). Both the groups responded well with respect to outcome measures like IPSS, Q\(_{\text{max}}\) (ml/sec) PVR with no inter-group difference (p = 0.249, p = 0.144, p = 0.942) (table II).

The evaluation of outcome at month 2 shows that IPSS and PVR were significantly less in tamsulosin group than those in alfuzosin group (p = 0.015 and p = 0.038 respectively). The Q\(_{\text{max}}\) responded well in both the
groups and with no significant difference between the groups (14.83 ± 0.38 vs. 14.26 ± 1.24 ml/sec, p = 0.453) (table II). The alfuzosin group had a significantly higher postural hypotension (44.4%), dizziness (100%), asthenia (97.2%) and GI tract upset (77.8%) compared to the tamsulosin group (p < 0.001, p = 0.001, p = 0.007 and p = 0.025) (table I).

However, tachycardia, headache and rhinitis were more common in the tamsulosin group than those in the alfuzosin group (p < 0.001, p = 0.023 and p < 0.001 respectively) (table IV). There was significant increase in Qmax relative to baseline in both the treatment groups at each interval (p < 0.001) (fig. 1). At the endpoint the alfuzosin group responded better than the tamsulosin group, though the difference between the two groups did not reach the level of significance (p = 0.453). Alfuzosin group experienced a steady decrease in IPSS from > 17 at baseline to < 14 at month 1 and to < 10 at the end month 2. The tamsulosin group also followed a similar pattern of decrease from a mean IPSS of 16.9 at baseline to < 9 at the end of month 2 (fig. 2). The difference between the two groups at the endpoint was significant (p = 0.015) (table II). The effects of alfuzosin and tamsulosin on blood pressure were summarized in table. At the endpoint there were significant reductions in all mean blood pressure variables in the alfuzosin group compared with baseline but not in patients treated with tamsulosin (p < 0.001). In the tamsulosin group the standing diastolic and supine diastolic blood pressures though decreased slightly in the 1st month of treatment, they again stabilized during 2nd month of treatment, while standing systolic and supine systolic blood pressures did not experience any change (figure 3-6). All the patients in both treatment groups exhibited an improvement of Qmax by ≥ 3 ml/s at the end of month 2 from baseline. However, improvement of total symptom score in terms of IPSS ≥ 25% from baseline was significantly higher in the alfuzosin group (88.9%) than that in the tamsulosin group (48.4%) (p < 0.001).

Discussion

The findings of the study demonstrated that both alfuzosin 10 mg and tamsulosin 0.4 mg as once-daily doses had reasonable efficacy in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign hyperplasia of prostate (BPH). The urinary flow (in terms of Qmax) and urinary tract symptoms (in terms of IPSS) both improved from their baseline status. The mean postvoid residual urine volume decreased dramatically from 87 and 115 ml to 62 and 58 ml in the alfuzosin and tamsulosin groups respectively. Roehrborn in an attempt to examine the efficacy and safety of once daily formulation of alfuzosin (10 mg daily) in a pooled analysis of three parallel, randomized, double-blind placebo controlled 3-month studies of patients having LUTS with BPH demonstrated a significant decrease in the mean IPSS in the experimental group (6 ± 5.1) than that in the placebo group (4.2 ± 5.7) (p < 0.005). The peak flow rate (PFR) decreased by 2.3 ml/sec in the former group and by 1.1 ml/sec in the latter group (I < 0.001). Buzelin demonstrated significant increase in Qmax relative to baseline in both alfuzosina and tamsulosin groups with mean increase in Qmax was around 1.6 ml/s. However, they used alfuzosin in a dose of 2.5 mg thrice daily and measured improvements in symptoms in terms of Boyarsky score. The mean reduction in total symptom score at endpoint was 4.1 in the tamsulosin group and 3.8 in the alfuzosin group. In the present study the percentage of patients with a ≥ 3 ml/s improvement in Qmax was 100% in both the groups. However, a significantly higher percentage of patients in alfuzosin group experienced a decrease in total symptom scores of ≥25% from baseline. In the Buzelin’s study a comparable percentage of patients in the two groups exhibited improvements at the endpoint of the study.

The indirect comparisons of the efficacy and tolerability of alfuzosin and tamsulosin using the data from the placebo-controlled studies for each drug suggest that both behave similarly clinically, despite several differences in their in vitro pharmacology profile. This conclusion is also supported by the results of a randomized, double-blind, direct comparative 12-week study, in which 256 patients with benign prostatic enlargements and lower urinary tract symptoms were treated with 2.5 mg alfuzosin three times daily or 0.4 mg tamsulosin once daily. Similarly, a recent nonrandomized study comparing standard alfuzosin (2.5 mg three times daily), tamsulosin (0.4 mg once daily), and terazosin (5 mg once daily) treatment for 6 months reported that all three drugs caused similar improvements in the IPSS and urodynamic parameters of obstruction.

It would be worthwhile to mention that an increased incidence of abnormal ejaculation relative to placebo has been reported in most studies with tamsulosin but not in those with alfuzosin, although the present study did not find any patients in either group with abnormal ejaculation. It may be due to chance error because the present study worked on a smaller sample, while Buzelin and other investigators worked on much larger sample size.

Thus, from a clinical viewpoint, alfuzosin and tamsulosin appear to be very similar in efficacy. The main difference between the two drugs is that tamsulosin had almost no effect in lowering the blood pressure. The standing
diastolic and supine diastolic blood pressures though
decreased slightly in the 1st month of treatment, they
again stabilized during 2nd month of treatment, while
standing systolic and supine systolic blood pressures did
not experience any change throughout the treatment
period. There are several other practical advantages of
using an α-1-adrenoceptors without antihypertensive
effects in the treatment of LUTS suggestive of BPH.
Both hypertension and LUTS due to BPH are highly
prevalent, age-related disorders. Population studies
suggest that about half of the elderly men aged 65 or
above 65 years may be hypertensive, similar to the
proportion of elderly men who suffer from LUTS due to
BPH. Not surprisingly therefore, that a significant
number of elderly men have both hypertension and
LUTS suggestive of BPH. Thus theoretically it
would appear to be an attractive option to treat these
patients with single pharmacological agent, i.e., an α-
adrenoceptor antagonist with antihypertensive properties.
However, about 30% of the patients with LUTS
suggestive of BPH are already receiving some form
antihypertensive treatment when they visit a urologist.
In such cases it is not desirable to interfere with their
established antihypertensive therapy as this may lead to
loss of blood-pressure control, require dose adjustment
of the existing antihypertensive medication or provoke
adverse events (e.g. orthostatic hypotension).

Monotherapy with α-1-adrenoceptor antagonists is,
therefore, not the preferred first step in the treatment of
most hypertensive patients. Finally, α1-adrenoceptor
antagonists are not the first choice for hypertensive
patients with coexisting cardiac disorders (e.g. angina
pectoris and/or heart failure). Logically, patients with
LUTS suggestive of BPH falling into categories, such as
these, may benefit from an α1-adrenoceptor antagonist
without antihypertensive effect. The present study
showed that tamsulosin (0.4 mg once daily) can provide
this treatment option; when compared with the non-
subtype-selective α-1-adrenoceptor antagonist alfuzosin
(10 mg as once-daily), tamsulosin had comparable
efficacy and tolerability in patients with LUTS
suggestive of BPH. However, tamsulosin did not
significantly reduce blood pressure (systolic and
diastolic) as much as alfuzosin. Alfuzosin's effect on
blood pressure and particularly the significant reduction
from their baseline status is specially pronounced in
elderly patients. Although alfuzosin is generally well
tolerated in normotensive men, elderly patients and those
with hypertension have increased sensitivity to
vasodilatation. Furthermore, the likelihood that
treatment with alfuzosin may be discontinued, because
(vasodilatory) adverse events are more marked in elderly
(> 75 years) patients with LUTS suggestive of BPH
having concomitant cardiovascular disease(s) and/or
taking concomitant cardiovascular medication(s). Because the therapeutic daily dose of alfuzosin in the
treatment of hypertension is 10 - 20 mg, whereas the
recommended dose in LUTS suggestive of BPH is 7.5 -
10 mg. The concomitant administration of non-subtype selective
α-1-adrenoceptor antagonists with antihypertensive
agents, particularly calcium antagonists is not
recommended because of potentiation of the
antihypertensive effects. In contrast, in hypertensive
patients whose blood pressure was controlled with an
antihypertensive agent (e.g. nifedipine or enalapril),
concomitant treatment with tamsulosin was shown not to
induce clinically relevant additional blood pressure
reduction. This confirms that tamsulosin is a feasible
treatment option for patients with LUTS suggestive of
BPH who are normotensive or hypertensive but well
controlled with conventional antihypertensives.

Table I. Comparison of baseline variables between
groups (n = 67).

<table>
<thead>
<tr>
<th>Baseline variables</th>
<th>Group</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alfuzosin (n = 36)</td>
<td>Tamsulosin (n = 31)</td>
</tr>
<tr>
<td>IPSS</td>
<td>17.3±1.1</td>
<td>16.9±1.7</td>
</tr>
<tr>
<td>Qmax (ml/sec)</td>
<td>11.5±0.6</td>
<td>11.1±1.0</td>
</tr>
<tr>
<td>PVR</td>
<td>87.2±10.7</td>
<td>115.8±12.2</td>
</tr>
<tr>
<td>Standing systolic BP</td>
<td>148.9±6.9</td>
<td>135.7±11.5</td>
</tr>
<tr>
<td>Standing diastolic BP</td>
<td>97.0±5.2</td>
<td>85.0±6.1</td>
</tr>
<tr>
<td>Lying systolic BP</td>
<td>143.7±7.0</td>
<td>132.3±11.3</td>
</tr>
<tr>
<td>Lying diastolic BP</td>
<td>91.0±4.0</td>
<td>80.5±6.3</td>
</tr>
</tbody>
</table>

* Data were analyzed using Student's t Test and level of significance was 0.05.

The α1-adrenoceptor antagonists were originally
developed for the treatment of hypertension. As it was
evident that α1-adrenoceptor subtype is primarily
present in the prostate and responsible for the contraction
of its smooth muscles, research—eye shifted from
treatment of hypertension with α1-adrenoceptor
antagonists to treatment of BPH causing LUTS with the
same agents. Like previous studies, the present study
also showed that tamsulosin (0.4 mg once-daily), when
compared with the non-subtype-selective α1-
adrenoceptor antagonist alfuzosin (10 mg once-daily),
had comparable efficacy and tolerability in patients with
LUTS suggestive of BPH. However, the lack of a
clinically significant reduction of blood pressure with
tamsulosin and its favourable efficacy/safety ratio may partly be the reason that the therapeutic dose of 0.4 mg once daily can be administered from the onset of therapy with no need for dose titration.

**Table II. Comparison of outcome at month 1 between groups (n = 67).**

<table>
<thead>
<tr>
<th>Outcome measures</th>
<th>Group</th>
<th>p-value $^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alfuzosin (n=36)</td>
<td>Tamsulosin (n=31)</td>
</tr>
<tr>
<td>IPSS</td>
<td>13.58 ± 1.36</td>
<td>13.10 ± 2.04</td>
</tr>
<tr>
<td>$Q_{max}$ (ml/sec)</td>
<td>13.08 ± 0.55</td>
<td>13.35 ± 0.88</td>
</tr>
<tr>
<td>PVR</td>
<td>74.64 ± 9.49</td>
<td>74.84 ± 12.81</td>
</tr>
</tbody>
</table>

Figures in the parentheses denote corresponding percentage.

$^a$ Data were analyzed using Student’s t-Test and level of significance was 0.05.

**Table III. Comparison of outcome at month 2 between groups (n = 67).**

<table>
<thead>
<tr>
<th>Outcome at month 2</th>
<th>Group</th>
<th>p-value $^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alfuzosin (n=36)</td>
<td>Tamsulosin (n=31)</td>
</tr>
<tr>
<td>IPSS</td>
<td>9.81 ± 0.71</td>
<td>8.84 ± 2.00</td>
</tr>
<tr>
<td>$Q_{max}$ (ml/sec)</td>
<td>14.83 ± 0.38</td>
<td>14.26 ± 1.24</td>
</tr>
<tr>
<td>PVR</td>
<td>62.50 ± 7.84</td>
<td>58.71 ± 6.58</td>
</tr>
</tbody>
</table>

Figures in the parentheses denote corresponding percentage.

$^a$ Data were analyzed using Student’s t-Test and level of significance was 0.05.

**Table IV. Comparison of adverse effects between groups (n = 67)**

<table>
<thead>
<tr>
<th>Adverse effects</th>
<th>Group</th>
<th>p-value $^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alfuzosin (n=36)</td>
<td>Tamsulosin (n=31)</td>
</tr>
<tr>
<td>Postural hypotension</td>
<td>16 (44.4)</td>
<td>2 (6.5)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>36 (100.0)</td>
<td>23 (74.2)</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>2 (5.6)</td>
<td>22 (71.0)</td>
</tr>
<tr>
<td>Headache</td>
<td>21 (58.3)</td>
<td>26 (83.9)</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>0 (0.0)</td>
<td>12 (38.7)</td>
</tr>
<tr>
<td>Asthenia</td>
<td>35 (97.2)</td>
<td>23 (74.2)</td>
</tr>
<tr>
<td>G1 tract upset</td>
<td>28 (77.8)</td>
<td>16 (51.6)</td>
</tr>
</tbody>
</table>

Figures in the parentheses denote corresponding percentage.

$^a$ Data were analyzed using Chi-square ($x^2$) or Fisher’s Exact Test as applicable.

**Table V. Comparison of improvements between groups (n = 67)**

<table>
<thead>
<tr>
<th>Improvements</th>
<th>Group</th>
<th>p-value $^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>$Q_{max}$ &gt; 3 ml/s from baseline</td>
<td>36 (100.0)</td>
<td>31 (100.0)</td>
</tr>
<tr>
<td>IPSS &gt; 25% from baseline</td>
<td>32 (88.9)</td>
<td>15 (48.4)</td>
</tr>
</tbody>
</table>

Figures in the parentheses denote corresponding %

$^a$ Data were analyzed using Chi-square Test.

**Reference**

5. Nordling J 2005. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005;95:1066-12.


